Press release
Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has ranked #1 on Fast Company’s fourth annual list of Best Workplaces for Innovators.\n\nThe 2022 Best Workplaces for Innovators ranks 100 winners from a variety of industries, including computer science, biotech, consumer packaged goods, nonprofit, education, financial services, cybersecurity, engineering, diversity, sustainability, B2B, and consumer products and services. Approximately 1,500 applications were scored, and a panel of eight eminent judges has reviewed and endorsed the top 100 companies. The 2022 awards feature workplaces from around the world.\n\n“It’s thrilling to be recognized as a top place to innovate in the year we are celebrating our 20th anniversary. Innovation and Discovery is one of Alnylam’s cherished core values and has been at the heart of this Company from day one,” said Akshay Vaishnaw, M.D., Ph.D., President of Alnylam. “Alnylam was founded and built by innovators, and we take great pride in providing an environment that continues to nurture innovation and ‘out of the box’ thinking. After all, patients’ lives depend on it.”\n\n“This year’s list of the Best Workplaces for Innovators recognizes organizations that have demonstrated a deep commitment to cultivating creativity across the board,” says Brendan Vaughan, editor-in-chief of Fast Company. “In the face of powerful headwinds, these leaders and teams continue to spur innovation.”\n\nAbout RNAi\n\nRNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as \"a major scientific breakthrough that happens once every decade or so,\" and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins,...